J 2019

Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study

PLUTINSKÝ, Marek, Kristián BRAT, Michal SVOBODA, Jaromir ZATLOUKAL, Patricie POPELKOVA et. al.

Basic information

Original name

Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study

Authors

PLUTINSKÝ, Marek (703 Slovakia, belonging to the institution), Kristián BRAT (703 Slovakia, guarantor, belonging to the institution), Michal SVOBODA (203 Czech Republic, belonging to the institution), Jaromir ZATLOUKAL (203 Czech Republic), Patricie POPELKOVA (203 Czech Republic) and Vladimir KOBLIZEK (203 Czech Republic)

Edition

LUNG, NEW YORK, SPRINGER, 2019, 0341-2040

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30203 Respiratory systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 1.817

RIV identification code

RIV/00216224:14110/19:00109670

Organization unit

Faculty of Medicine

DOI

UT WoS

000466205900009

Keywords in English

COPD; GOLD classification; Prognosis; Mortality

Tags

Tags

International impact, Reviewed
Změněno: 16/5/2019 14:44, Soňa Böhmová

Abstract

V originále

Recent research showed group B patients express higher mortality compared to group C patients when GOLD A-D grouping is used. We aimed to compare the prognostic accuracy of three GOLD classification systems, I-IV (pre-2011), A-D (2011-2016) and A-D (2017-present) in relation to mortality, exacerbation risk, quality of life (QoL) assessment and specific treatments use in a real-life COPD cohort. We used the data of 720 patients from the Czech Multicenter Research Database of COPD. Four-year mortality and time-to-exacerbation using the GOLD pre-2011, 2011-2016 and 2017-present classification schemes were assessed. Moreover, distribution of specific treatments use and QoL measures were analyzed. The GOLD I-IV classification system showed gradual increase in 4-year mortality across the stages (GOLD II 18.8%, III 28.5%, IV 38.7%) (p=0.001). Using the A-D 2011-2016 classification scheme, group C patients had lower mortality (16.7%) than group B (18.7%) (p=0.009). The A-D 2017-present classification showed higher mortality in group B (25.5%) compared to group C (20%) (p=0.05). For additional outcomes, the GOLD I-IV scheme showed highest match between the calculated 4-year exacerbation risk and QoL measures and GOLD stage/grouping. In terms of specific treatment distributions, various patterns for each GOLD classification system were observed with best match of GOLD 2017-present system to the layout of GOLD groups and categories. We conclude the GOLD I-IV classification system had the highest accuracy related to mortality, QoL measures and exacerbation risk prediction, while the A-D 2017-present scheme was most accurate within severity of symptoms prediction reflected also by more frequent specific treatments use.